Previous 10 | Next 10 |
Exicure , Inc. ® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced presentations in the following scientific conferences during the month of October: 17th International C...
Exicure , Inc. ® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced a presentation at the Chardan Virtual 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021. ...
Exicure , Inc. ® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that CEO David Giljohann will present at the Benzinga Healthcare Small Cap Conference on Thursday, September ...
Exicure , Inc. ® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced participation in the following scientific conferences during the month of September: TIDES USA 2021 ...
The following slide deck was published by Exicure, Inc. in conjunction with this event. For further details see: Exicure (XCUR) Corporate Overview
Exicure , Inc. ® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced participation in the following investor conferences during the month of September: Citi’s 16th A...
Entered Exclusive Collaboration with Ipsen Targeting Two Rare Neurodegenerative Disorders Presented Progress in Three Promising Neuroscience Programs including Friedreich’s Ataxia, Neuropathic Pain and Batten Disease at R&D Day Announced Interim Results for ...
Response rate threshold achieved to continue advancing patient enrollment in Phase 2 Merkel cell carcinoma (MCC) dose-expansion cohort Confirmed overall response rate (ORR) of 21% in all evaluable MCC patients enrolled in the Phase 1b/2 study Median duration of four ...
Exicure , Inc. ® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that CEO David Giljohann will present at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 ...
Gainers: Ever-Glory International Group (NASDAQ:EVK) +122%. Infinity Pharmaceuticals (NASDAQ:INFI) +33%. Exicure (NASDAQ:XCUR) +34%. Xenetic Biosciences (NASDAQ:XBIO) +31%. Atlas Technical Consultants (NASDAQ:ATCX) +28%. Annovis Bio (NYSE:ANVS) +22%. Full Truck Alliance (NYSE:YMM) +21%. Allie...
News, Short Squeeze, Breakout and More Instantly...
Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activiti...
Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on April 17, 2024 notifying the Company that, as a result of the Company’s failure to timely f...
GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...